BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8001709)

  • 21. Prevention of the complications of diabetes.
    Vinik AI; Vinik E
    Am J Manag Care; 2003 Mar; 9(3 Suppl):S63-80; quiz S81-4. PubMed ID: 12653455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes.
    Ceriello A
    Curr Opin Lipidol; 2006 Oct; 17(5):510-8. PubMed ID: 16960499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
    Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
    Saraswat M; Muthenna P; Suryanarayana P; Petrash JM; Reddy GB
    Asia Pac J Clin Nutr; 2008; 17(4):558-65. PubMed ID: 19114390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma homocysteine and microvascular complications in type 1 diabetes.
    Vaccaro O; Perna AF; Mancini FP; Iovine C; Cuomo V; Sacco M; Tufano A; Rivellese AA; Ingrosso D; Riccardi G
    Nutr Metab Cardiovasc Dis; 2000 Dec; 10(6):297-304. PubMed ID: 11302003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diabetic microangiopathy--its biochemical bases].
    Kawazu S; Tomono S
    Nihon Rinsho; 1991 Feb; 49 Suppl():34-42. PubMed ID: 1827848
    [No Abstract]   [Full Text] [Related]  

  • 27. [Screening of subjects at high risk for diabetic microangiopathies].
    Grimaldi A; Davidoff P
    J Mal Vasc; 1989; 14(1):57-63. PubMed ID: 2646389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactions between the sorbitol pathway, non-enzymatic glycation, and diabetic vascular dysfunction.
    Ido Y; Kilo C; Williamson JR
    Nephrol Dial Transplant; 1996; 11 Suppl 5():72-5. PubMed ID: 9044312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular understanding of hyperglycemia's adverse effects for diabetic complications.
    Sheetz MJ; King GL
    JAMA; 2002 Nov; 288(20):2579-88. PubMed ID: 12444865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative therapeutic principles in the prevention of microvascular and neuropathic complications.
    Gries FA
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S201-7. PubMed ID: 8529515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pathobiochemistry of the late-onset diabetic syndrome].
    Wieland OH
    Ther Ggw; 1974 Sep; 113(9):1448-63. PubMed ID: 4280154
    [No Abstract]   [Full Text] [Related]  

  • 32. [Diabetic microangiopathy--pathogenesis].
    Hotta N; Sakamoto N
    Nihon Rinsho; 1991 Feb; 49 Suppl():25-33. PubMed ID: 1903463
    [No Abstract]   [Full Text] [Related]  

  • 33. Manifestations of cutaneous diabetic microangiopathy.
    Ngo BT; Hayes KD; DiMiao DJ; Srinivasan SK; Huerter CJ; Rendell MS
    Am J Clin Dermatol; 2005; 6(4):225-37. PubMed ID: 16060710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular targets of diabetic vascular complications and potential new drugs.
    Da Ros R; Assaloni R; Ceriello A
    Curr Drug Targets; 2005 Jun; 6(4):503-9. PubMed ID: 16026269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The link between hyperglycaemia and diabetic nephropathy.
    Larkins RG; Dunlop ME
    Diabetologia; 1992 Jun; 35(6):499-504. PubMed ID: 1612221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycosylation of proteins and microangiopathy.
    Brownlee M
    Hosp Pract (Off Ed); 1992 Feb; 27 Suppl 1():46-50. PubMed ID: 1347540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications.
    Obrosova IG
    Antioxid Redox Signal; 2005; 7(11-12):1543-52. PubMed ID: 16356118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucose and diabetic vascular disease.
    Ruderman NB; Williamson JR; Brownlee M
    FASEB J; 1992 Aug; 6(11):2905-14. PubMed ID: 1644256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetic vascular complications.
    Cooper ME; Gilbert RE; Jerums G
    Clin Exp Pharmacol Physiol; 1997; 24(9-10):770-5. PubMed ID: 9315387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular complexities underlying the vascular complications of diabetes mellitus - A comprehensive review.
    Paul S; Ali A; Katare R
    J Diabetes Complications; 2020 Aug; 34(8):107613. PubMed ID: 32505477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.